Navigation Links
Leukemia drug could save lives of stroke patients
Date:6/22/2008

(New York, June 22). The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms. After that, tPA may cause dangerous bleeding in the brain. However, in a study published today in Nature Medicine, investigators from the Stockholm Branch of the Ludwig Institute for Cancer Research (LICR) and the University of Michigan Medical School show that these problems might be overcome if tPA is combined with the leukemia drug, imatinib (Gleevec). The results demonstrate that imatinib greatly reduces the risk of tPA-associated bleeding in mice, even when tPA was given as late as five hours after the stroke had begun. The LICR team, in collaboration with the Karolinska University Hospital in Stockholm, is now planning a clinical trial with imatinib in stroke patients.

According to the World Health Organization (WHO), 80 percent of the 15 million strokes that occur each year are caused by the type of blood clots in the brain that tPA can dissolve. Today, less than 3% of patients with this type of stroke receive tPA because the narrow safety window has often passed by the time a stroke patient reaches a hospital and is diagnosed. If the planned clinical trial with stroke patients in Sweden confirms the findings of the present study, there is great promise that imatinib or similar drugs could be administered to stoke patients to increase the therapeutic window of tPA.

The basis for this novel proposal is the key growth factor PDGF-CC, which has now been discovered to control the blood brain barrier (a structure that normally shields the brain from the blood). When tPA acts on PDGF-CC, the blood-brain barrier becomes porous and can start to leak. Imatinib inhibits the detrimental effect of PDGF-CC by binding to its receptor PDGFR alpha, seemingly without hindering tPA's therapeutic effect, which is to break down clots that have lodge
'/>"/>

Contact: Sarah White
swhite@licr.org
917-379-0398
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 18, 2014 A+ Secure Packaging, ... nutraceutical, dietary supplements and more, announced today that ... Good Manufacturing Practices (GMP) Registration for dietary supplements ... from NSF International verifies the A+ Secure Packaging ... compliance requirements of its clients by demonstrating the ...
(Date:11/18/2014)... 2014 Recently, Wigsbuy has introduced its ... are offered at greatly discounted prices now, up to 85% ... of human hair products, offering many real and synthetic hair ... global customers, Wigsbuy uses high quality materials to make its ... with the trend. , “We are offering a full ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. 17, ... not have significant heart-health benefits for older people, new ... than 14,000 Japanese people aged 60 to 85, found ... attacks and strokes between people who took aspirin and ... prevention with daily low-dose aspirin does not reduce the ...
(Date:11/18/2014)... By Dennis Thompson HealthDay ... doctor from Sierra Leone who became infected with Ebola in his ... Dr. Martin Salia had arrived Saturday at Nebraska Medical Center ... at a hospital in Sierra Leone,s capital city of Freetown. ... that have been ravaged by the Ebola outbreak that began last ...
(Date:11/17/2014)... 17, 2014 A Diet Doc ... throughout the country are turning back the clock on ... This is because the company has recently added their ... impressive collection of prescription and non-prescription diet products and ... Diet Doc’s best anti-aging human growth hormone ...
Breaking Medicine News(10 mins):Health News:A+ Secure Packaging, LLC Earns NSF International Good Manufacturing Practices (GMP) Registration for Dietary Supplements and Certification for Sport 2Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Doctor With Ebola Dies at Nebraska Hospital 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3
... Lower pay, fewer marriages among those who had depression, ... 17 (HealthDay News) -- Children who experience psychological disorders ... headed for a financially depressed adulthood, new research suggests. ... are less likely to get married or maximize their ...
... ... Village at ProprietorsGreen, a luxury senior rental community developed by Norwell-based ... has opened in Marshfield, Massachusetts. Despite an economic climate that ... on schedule, and opened with 40 percent of its independent living ...
... ... provider of solutions for the workers, compensation and liability markets, announced that it has ... drug requirements pertaining to Medicare Set-Asides (MSA). , ... Tampa, Florida (Vocus) May 17, 2010 -- PMSI ...
... diseases in middle age, despite an absence of family history ... blame, according to a new study conducted by researchers at ... the National Institutes of Health. The study also ... help identify those genetic abnormalities and allow detection before the ...
... the Queensland Institute of Medical Research (QIMR) and the Royal ... successfully treated it by performing an experimental stem cell transplant. ... out of hospital Katie Pulling had almost given up hope. ... the doctors say, ,We don,t know what is wrong, ,We ...
... ... for. Flexible Assembly Systems uncovers the great torque screwdriver mystery with its very own Torque ... (PRWEB) ... know what to look for. A torque screwdriver comes in many different variations, including ...
Cached Medicine News:Health News:Kids' Psychological Problems Have Long-Term Effects 2Health News:Village at Proprietors Green Opens on South Shore, Introducing Innovative Senior Living to Boston Area 2Health News:PMSI Advocacy Efforts Prompt CMS to Improve MSA Review Methodology 2Health News:PMSI Advocacy Efforts Prompt CMS to Improve MSA Review Methodology 3Health News:Lung disease may be genetic, despite lack of family history 2Health News:Australian researchers identify a new disease 2Health News:Flexible Assembly Systems Announces Torque Screwdriver Application Guide 2
(Date:11/18/2014)... ResMed (NYSE: RMD ), a leading ... first non-contact, personal sleep monitoring device. ResMed today announced S+ ... States and from the Apple Online Store ( ... with Apple HealthKit in iOS8 to give consumers an easy-to-read, ... report can also be shared with health care providers. ...
(Date:11/18/2014)... Nov. 18, 2014  A new global survey of ... a large majority of the general public feel they ... devastating disease that is responsible for 1.59 million deaths ... 1,2,4 . The "Any One Any Lung" survey uncovered ... widespread impact of lung cancer, but also a critical ...
(Date:11/18/2014)... Nov. 18, 2014  Palatin Technologies, Inc. ... targeted, receptor-specific peptide therapeutics for the treatment ... and commercial potential, today announced results for ... Recent Highlights , ... , €7.5M ($9.8M) total upfront payment - ...
Breaking Medicine Technology:ResMed's New S+ Consumer Sleep Monitor Now Integrates With Apple HealthKit 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 3Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 4Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 5Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 6Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 2Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 4Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 5Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 6Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 7
... Jan. 28, 2011 Endo Pharmaceuticals (Nasdaq: ... a collaboration agreement with European-based Orion Corporation for the ... The formation of this R&D collaboration partnership ... eight "discovery phase" candidates by combining an equal number ...
... 27, 2011 Sanofi-aventis (EURONEXT: SAN and ... Sciences, today announced that a randomized Phase III trial ... cancer (mTNBC) did not meet the pre-specified criteria for ... survival. Importantly, the results of a pre-specified ...
Cached Medicine Technology:Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration 2Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration 3Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration 4Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration 5Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer 2Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer 3Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer 4Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer 5
... head cap systems are packaged to provide ... Electro-Cap System features pure tin electrodes positioned ... you place your order, please specify which ... cap system and whether you want regular ...
... The Bio-eye hydroxyapatite (HA) orbital implant ... in the early 1980s, after a comprehensive ... which included the earliest manuscripts dating back ... with an ongoing dissatisfaction with the performance ...
... Philips HeartStart Home Defibrillatorthe latest in ... 175,000 devices deployed, Philips is the ... on airplanes, and in airports, workplaces, ... Home Defibrillator is the first and ...
... Cadwell's custom bars have a large ... machined contacts (spaced 3 centimeters center-to-center) ... of repeated cleaning. Polarity indicators are ... snap-on handle fits our bar electrode ...
Medicine Products: